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Abstract
Objective: Subchondral bone modifications occur early in the development of osteoarthritis (OA). The level of bone
resorption might impact cartilage remodeling. We therefore assessed the in vivo and in vitro effects of targeting bone
resorption in OA and cartilage metabolism.
Methods: OA was induced by meniscectomy (MNX) in ovariectomized osteopenic mice (OP) treated with estradiol (E2),
pamidronate (PAM), or phosphate buffered saline (PBS) for 6 weeks. We assessed the subchondral bone and cartilage
structure and the expression of cartilage matrix proteases. To assess the involvement of bone soluble factors in cartilage
metabolism, supernatant of human bone explants pre-treated with E2 or PAM were transferred to cartilage explants to
assess proteoglycan release and aggrecan cleavage. OPG/RANKL mRNA expression was assessed in bone explants by real-
time quantitative PCR. The role of osteoprotegerin (OPG) in the bone-cartilage crosstalk was tested using an OPG
neutralizing antibody.
Results: Bone mineral density of OP mice and osteoclast number were restored by E2 and PAM (p,0.05). In OP mice, E2 and
PAM decreased ADAMTS-4 and -5 expression, while only PAM markedly reduced OA compared to PBS (2.060.63 vs
5.260.95; p,0.05). OPG/RANKL mRNA was increased in human bone explants treated with both drugs (2.2–3.7-fold).
Moreover, supernatants from bone explants cultured with E2 or PAM reduced aggrecan cleavage and cartilage
proteoglycan release (7368.0% and 80622% of control, respectively, p,0.05). This effect was reversed with
osteoprotegerin blockade.
Conclusion: The inhibition of bone resorption by pamidronate in osteopenic mice alleviates the histological OA score with a
reduction in the expression of aggrecanases. Bone soluble factors, such as osteoprotegerin, impact the cartilage response to
catabolic factors. This study further highlights the importance of subchondral bone in the regulation of joint cartilage
damage in OA.
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Introduction
Osteoarthritis (OA) is a common disease responsible for high
morbidity related to functional disability and pain. Although
cartilage lesions are the main feature of OA, other joint structures
also contribute to progression of the disease via several
mechanisms. Radin et al. [1,2] was the first to suggest that
subchondral bone could trigger degradation of the overlying
cartilage. Subsequently, studies on humans and animal models
have revealed concomitant changes in bone and cartilage
structures, particularly during the late stages of OA. In patients
with established OA, trabecular bone volume is high, and bone
accretion is correlated with the severity of cartilage damage [3].
Subchondral bone lesions appear during the early stages of OA, as
demonstrated by the presence of bone marrow lesions that are
factors predictive of OA progression [4,5]. The natures of such
bone lesions are still poorly established, although trabecular
fractures or enhanced trabecular bone remodeling are suspected.
Early stages of OA are accompanied by a decrease in bone
volume, which suggests that initial bone resorption might trigger
OA [6–9]. Indeed, OA can be prevented in rats by inhibiting bone
resorption with alendronate [6]. Several molecules may mediate
osteoclastic bone resorption, and thus have an impact on cartilage
remodeling [10]. We and others have demonstrated that
osteoprotegerin (OPG), a decoy receptor of Receptor Activator
for Nuclear Factor kB Ligand (RANKL) produced by osteoblasts,
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joint instability [10,11]. Reducing bone remodeling in Runx2
transgenic mice prevents from cartilage breakdown [12].
The role of bone resorption related to estrogen failure in the
development of OA is still a matter of debate. In humans, estrogen
deficiency is reported to be a risk factor for OA, and estrogen
deficiency/polymorphism appears to increase the incidence of OA
in postmenopausal women [13–16], although this remains
controversial [17]. In mice, the deletion of estrogen receptors
does not affect the cartilage structure [18], whereas protective
effects of estradiol in the development of OA have been shown in
other animal models [19,20]. Estrogens are powerful osteoclast
inhibitors [21], and might contribute to OA protection via their
effects in bone.
The aim of this study was to assess whether cartilage protection
could be achieved by inhibiting bone remodeling in mice with high
bone resorption induced by estrogen deficiency. We therefore
investigated the impact of reducing bone resorption in osteopenic
mice (OP) with joint instability, and the effects of bone-secreted
cytokines on cartilage catabolism.
Results
Inhibitors of bone resorption restore subchondral bone
architecture in OP mice
The bodyweight of mice remained stable in each group
throughout the study (Table 1). Uterus weight declined after
ovariectomy in the Phosphate Buffered Saline (PBS)-treated and
Pamidronate (PAM)-treated mice, but was maintained in the mice
treated with estradiol. Total body BMD decreased significantly in
OP mice (p,0.05), and this was reversed by both pamidronate
and estradiol. These results indicate an appropriate systemic
response to both anti-resorptive therapies. BMD changes in the
knee were in line with those of total body BMD.
Bone indices were measured at the tibia 6 weeks after MNX.
Bone volume (BV/TV) was lower in OP mice than in controls,
which was consistent with the increase in Tb.Sp and osteoclast
number, and the lower Tb.Th (Table 2). Estradiol prevented the
local bone loss observed in the OP-PBS mice (48.864.8% vs
27.663%, p=0.005), and also prevented the increase in trabecular
spacing and osteoclast number. The effects of estrogens on the local
microarchitecture wereinline with theireffectsonsystemic bone.In
contrast, pamidronate-treated mice had significantly lower osteo-
clast numbers, but no significant changes were observed in BV/TV
(30.764.6% vs 27.663%, p=0.48), although BMD data indicated
that this treatment did prevent systemic bone loss.
Anti-resorptive agents protected mice against OA
The histological OA score was significantly greater after MNX
than in the sham-operated knees (5.160.47 vs 0.560.18,
respectively; p=0.018) (Figure 1). However, OP did not produce
any further increase in the OA score compared to controls
(5.260.95; p=0.86). In MNX knees, pamidronate provided
significant reduction of cartilage degradation compared to PBS
treatment (OARSI 2010 score: 2.060.63 vs 5.260.95; p=0.042).
In contrast, the effect of estradiol was not significant, although a
similar trend was observed (3.761.30; p=0.18) (Figure 1). These
results show that pamidronate reduced OA in a context of high
systemic bone resorption whereas estradiol deficiency or supple-
mentation had no significant structural effects on cartilage
degradation induced by MNX.
To further investigate the biochemical changes in cartilage in each
group, we analyzed the expression of ADAMTS by immunohisto-
chemistry (Figure 2). MNX increased the expression of ADAMTS-4
and ADAMTS-5 in chondrocytes compared to controls (positive cells
for ADAMTS-4 and -5: 58.163.5% vs 38.865.8%; p=0.017;
22.964.7% vs 7.564.3%; p=0.027, respectively). The number of
ADAMTS-4 expressing cells was lower after estradiol and pami-
dronate than in PBS-treated mice (45.265.9%, and 37.065.6%, vs
60.263.0%, p=0.025 and p=0.01 respectively). Similar results were
observed with ADAMTS-5 (14.262.9% and 7.1064.7% vs
34.566.1%, p=0.025 and p=0.039, respectively, Figure 2).
Thus, estradiol and pamidronate both reduced aggrecanase
expression, whereas only pamidronate significantly decreased the
OA score induced by MNX.
Bone supernatants reduced human cartilage explants
breakdown
To further understand the crosstalk between bone and cartilage,
we investigated whether the conditioned media of bone explants
contributed to the cartilage breakdown. IL-1b alone or in addition
to the supernatants of control bone explants induced a significant
increase in proteoglycan release from cartilage explants
(123.962.4% and 132616% of controls, respectively, p,0.05)
(Figure 3). Moreover, culture supernatant from bone pre-treated
with estradiol at 0.01 mMo r1mM, or with pamidronate at 1 mM,
was able to reverse cartilage breakdown (10268.0%, 7368.0%
and 80622% of control, respectively, p,0.05) (Figure 3A). The
expression of aggrecan neoepitopes (ARGS
374 sequences) was high
in baseline conditions, the cartilage explants being harvested from
patients with severe OA. However, this level was reduced by
adding the supernatant of bone cultured with pamidronate, but
not with the 2 doses of estradiol (Figure 3B).
Table 1. Effect of bone resorption inhibitors on bone indices in osteopenic mice with joint instability.
Controls Osteopenic mice
PBS E2 PAM
Body weight (g) 22.160.52 22.460.64 23.960.50 21.460.42
Uterus weight (mg) 47632 5 641 6866* 35615
DBMD Total body (g/cm
2) 0.03960.006 20.02760.0231 0.12460.0141*0 . 1 1 9 60.0 181*
DBMD Left knee (g/cm
2) 0.05360.024 20.06560.0351 0.17860.0481*0 . 1 8 9 60.0101*
DBMD Right knee (g/cm
2) 0.14160.023 20.06360.0481 0.21660.0431*0 . 2 3 1 60.0281*
1: compared to controls, p,0.05.
*: compared to PBS, p,0.05.
doi:10.1371/journal.pone.0033543.t001
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To find out whether cytokines were involved in this effect, the
expressions of RANKL and OPG transcripts were measured.
Adding IL-1b did not increase the OPG/RANKL mRNA ratio in
bone explants (1.260.55 times control, p=0.43, Figure 4A). Bone
cultured with E2 showed a significant, dose-dependent increase in
the OPG/RANKL ratio (2.960.16 and 3.761.3 times control, at
0.01 and 1 mM, respectively, p=0.019), as did those cultured with
PAM (2.260.9 times control, p=0.028). To find out whether the
effect of conditioned bone cultures was mediated by OPG, OPG
neutralizing antibody was added to the bone culture medium
before it was transferred onto cartilage explants. We observed that
OPG neutralization reversed the protective effects of E2 and PAM
on aggrecanase neoepitopes expression (Figure 4B).
Discussion
In this study, we show that regulating the level of bone
remodeling in OP mice modulates the response of cartilage to
meniscetomy. The inhibition of high bone resorption, here
induced by ovariectomy, reduced cartilage lesions and the increase
in both ADAMTS-4 and ADAMTS-5, the main aggrecanases
involved in OA [22,23]. These results are consistent with our
previous observations showing that pamidronate reduced cartilage
damage in Runx-2 transgenic mice with high bone resorption, but
had no effect in control littermates with normal bone remodeling
Figure 1. Histological assessment of cartilage lesions. A. OA scored according to the 2010 OARSI recommendations. The score represents the
sum of the grades at the tibia and femur in sagittal sections. B. Magnifications of slides stained with safranin-O (406) in control mice (a: Sham
operated knees; b: MNX knees; n=8) and osteopenic (OP) mice treated with phosphate buffered saline (PBS) (c; n=10), estradiol (E2) (d; n=6), or
pamidronate (PAM) (e; n=5). *: p,0.05.
doi:10.1371/journal.pone.0033543.g001




BV/TV (%) 4262.8 27.6631 48.864.8* 30.764.6
Tb.Th (mm) 12.560.98 9.860.531 11.461.03 10.0360.88
Tb.Sp (mm) 17.5613.6 28.663.41 12.661.7* 24.564.8
Tb.N (/mm) 0.03460.002 0.02860.003 0.04360.004* 0.03060.004
Oc.N/BV (/mm
2) 17.466.3 45.7610.51 21.4610.6* 19.967.9*
1: compared to controls, p,0.05.
*: compared to PBS, p,0.05.
doi:10.1371/journal.pone.0033543.t002
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only in mice with high resorption, suggesting that its action is
driven by bone. Thus, in the murin model of OA by joint
instability, the inhibition of high osteoclast activity has some
protective effects on the overlying cartilage.
At 6 weeks after MNX, ovariectomy induced no additional
damage, in contrast with previous observations in rats or rabbits
[24,25]. In our study, the effect of ovariectomy could have been
minimized by the local effect of MNX. Mice were treated with
estrogens or with pamidronate to target osteoclast formation.
Along with the reduction of osteoclast number, pamidronate
reduces cartilage structural lesions both at the tissue and cellular
level. Estrogens, that inhibit osteoclasts, failed to provide
significant protection against cartilage structural lesions, despite
reducing ADAMTS expression. However, subchondral bone was
restored with estrogens along with the prevention of systemic bone
Figure 2. Expression of ADAMTS-4 and ADAMTS-5 in joint cartilage. A. Immunostaining for ADAMTS-4 in cartilage. Bars represent the
percentage of positive cells. B. Immunostaining for ADAMTS-5 in cartilage. C. 406magnification of ADAMTS-4 & ADAMTS-5 expression in the tibial
joint cartilage in Sham operated knees (a–g), and MNX knees (b–h) of control mice, and in MNX knees from OP mice treated with phosphate buffered
saline (PBS) (c–i), estradiol (E2) (d–j) or pamidronate (PAM) (e–k), with corresponding negative controls (f–l). *: p,0.05. **: p,0.01.
doi:10.1371/journal.pone.0033543.g002
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differential impacts on subchondral and trabecular bone in OP
mice. These results demonstrate the role of subchondral bone, and
in particular of osteoclast activity, in the initiation of OA lesions.
Despite clinical evidence showing that OA is more frequent in
women, the contribution of estrogen in the pathogenesis of OA
remains unclear and might be mediated by the effects of bone
resorption. Estradiol modulates the chondrocyte phenotype in vitro
via both the ERa and ERb receptors [26–29]. In vivo, studies have
shown that ovariectomy has harmful effects on joint cartilage [8],
but conflicting findings have also been reported [19,30].
Osteoporosis induced in rabbits using both ovariectomy and
corticosteroids experienced cartilage damage [8] further indicating
that cartilage lesions might be induced by bone signals in addition
to a direct effect on chondrocytes.
To investigate the mechanisms by which bone cell activity could
modulate cartilage metabolism, we transferred supernatant of
human subchondral bone cultures on cartilage explants. Indeed,
we found that the release of proteoglycan and aggrecan
neoepitopes in cartilage cultures was reduced by bone superna-
tants cultured with estradiol and pamidronate, indicating that
bone-secreted soluble factors are involved in regulating cartilage
catabolism. Since chondrocytes express RANK and RANKL [31–
34] and treatment with OPG showed protective effects in the joint
instability model [10,11], we speculated that OPG could mediate
the effect of estradiol or pamidronate. Hence, we found that the
OPG/RANKL ratio was significantly higher in bone explants
cultured in the presence of estradiol and pamidronate. The
inhibition of OPG in the bone culture medium transferred into
cartilage cultures resulted in a marked increase in aggrecanase
activity, demonstrating the role of OPG in the regulation of
cartilage catabolism. Indeed, OPG/RANKL ratio is reduced in
subchondral bone of OA rabbits with osteoporosis [8] as well as in
rat mandibular condyles [33]. The effect of OPG can be mediated
by its interaction with TRAIL, and thus via regulation of
chondrocyte apoptosis, as suggested by Shimizu et al. [11]. Taken
together, these data indicate that OPG and RANKL are involved
in a two-way crosstalk between bone and joint cartilage, regulating
both cartilage catabolism and subchondral bone resorption. How
these tissues can communicate has long been a subject of debate
given the absence of vascularization in cartilage, and the high
mineralization of calcified cartilage. In addition to the neo-
vascularization of subchondral bone, the diffusion of local factors
through bone clefts or through canaliculae in calcified cartilage
seems likely to occur [35].
In conclusion, our study shows that bone is implicated in the
mechanisms leading to OA, and that the level of bone remodeling
modulates how cartilage responds to joint instability. Moreover,
OPG is an essential factor that regulates cartilage catabolism. This
study further highlights bone as a target for the treatment of OA.
Methods
Animals
Ten week-old female C57/Bl6 mice underwent medial
meniscectomy (MNX) of the right knee to induce joint instability,
as previously described [10]. A sham operation was performed on
the left knee. To increase bone resorption, we induced osteopenia
(OP) by ovariectomy and treated mice by two different bone
resorption inhibitors: estradiol and a bisphosphonate (pamidro-
nate) to inhibit osteoclast activity. All ovariectomies were
performed in a random order regardless of the groups. After
meniscectomy, mice were divided into 4 groups:
– 3 groups of 5–10 animals underwent bilateral ovariectomy to
induce OP. These mice received either subcutaneous daily
injections of 17b estradiol (15 mg/kg/d, OP-E2), or intra-
peritoneal injections of pamidronate (30 mg/kg/w, OP-PAM),
or Phosphate buffered saline (100 ml, OP-PBS).
– 1 group was sham operated without ovariectomy, and was used
as the control group.
Mice were pair-fed in order to control for bodyweight, and were
sacrificed 6 weeks after surgery. The uterus was removed and
weighed.
Figure 3. Bone mediated effects of estradiol and pamidronate
on proteoglycan and aggrecan neoepitopes release by human
cartilage explants. A. Proteoglycan release in cartilage supernatants.
IL1-b stimulated cartilage explants were cultured with media from bone
explants previously cultured with estradiol at 0.01 mM (E-8) or 1 mM (E-
6) or pamidronate at 1 mM (PAM) or with control medium (M). Results
are the mean 6 SEM of 3 different experiments performed in triplicate.
B. Aggrecan neoepitopes expression (ARGS
374 sequences) in cartilage
supernatants. Image of a representative Western blot. The overlying
graph represents the mean quantification 6 SEM of 3 different
experiments. Quantification was done on the 50 kDa bands.
*: compared to control, p,0.05. 1: compared to IL-1b stimulation of
cartilage, p,0.05.
doi:10.1371/journal.pone.0033543.g003
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Lunar Piximus (GE Healthcare, WI, USA) at baseline and at
sacrifice (BMD, g/cm
2) in order to assess whether the doses of
estradiol and bisphosphonate were appropriate. The relative
change in BMD from baseline to sacrifice (DBMD) was calculated
as (BMD at sacrifice - BMD at baseline)/BMD at baseline.
The experiments complied with the Guidelines for Animal
Experimentation issued by the local Ethics Committee on Animal
Care and Experimentation (Ethical committee Lariboisie `re-
Villemin, Paris, France). This committee specifically approved
this study.
Preparation of mouse joint samples
Whole knee joints were dissected free of soft tissues. Specimens
were fixed with 4% PFA (pH 7.4) for 24 h at 4uC, and then
decalcified with 1% PFA-0.2 M EDTA (pH 7.4, 4uC) for 2 weeks,
changing the solution twice a week. The specimens were then
dehydrated using increasing concentrations of ethanol, before
being embedded in paraffin. Five-mm thick serial sagittal sections
were cut in the medial femoro-tibial compartment for histology
and immunohistochemistry procedures.
Histology and immunohistochemistry
We assessed the histological OA score on slides stained with
safranin-O. Sections were deparaffinized by two successive 20-
minute immersions in xylene baths. They were then rehydrated by
immersion for 1 min in each of 3 successive baths containing
100%, 70%, and 40% alcohol, respectively, before being washed
twice by 5-min immersions in baths of distilled water. Sections
were stained using Mayer-Hemalum staining for 5 min to stain the
nuclei, and then counterstained with 0.125% Fast Green for
2 minutes to visualize bone tissue. After being rinsed in two
successive 1% acetic acid baths, they were stained in 0.5%
Safranin-O in the same bath, and then rinsed in 95% ethanol. All
stained sections were then rinsed with distilled water. Osteoar-
thritic lesions were determined using the OARSI 2010 score with a
scale ranging from stage 0 (normal) to 6 (vertical clefts/erosion to
the calcified cartilage extending over .75% of the joint surface) on
both the tibial and femoral articular cartilage, resulting in a global
score of 0 to 12 [36].
Immunohistochemistry was performed on serial sections, as
previously described [10]. Vector kit (PK-6101, from Abcys,
France) was used according to the Manufacturer’s instructions,
and sections were counterstained with toluidine blue. Primary
polyclonal antibodies directed against murine ADAMTS-4 and
ADAMTS-5 (ab28285 and ab41037, respectively, Abcam, United-
Kingdom) were used to assess aggrecanase expression and activity.
Positive cells were counted on the tibial joint cartilage surface (256
magnification), and expressed as a percentage of the total cell
count.
Histomorphometry of subchondral bone
Bone parameters were measured on slides stained with Fast-
Green. Microarchitectural indices of the underlying bone were
assessed in total epiphyses by an image analyzer using specially
designed software (Bonolab, MicrovisionH, France). For each
section, the bone between the cartilage and the growth plate was
analyzed, and measured as follows:
– Bone Volume/Tissue Volume (BV/TV, %)
– Trabecular Thickness (Tb.Th, mm), which reflects bone
formation
Figure 4. OPG exerts protective effects on cartilage catabolism. A. OPG/RANKL mRNA ratio in IL1-b stimulated bone explants cultured with
estradiol at 0.01 mM (E-8) and 1 mM (E-6), and with pamidronate (PAM). The graph represents the mRNA ratio to controls in 3 different experiments. B.
Effect of OPG blockade by a neutralizing antibody (OPG-ab) on ARGS
374 sequences expression in supernatants of cartilage explants cultured with
conditioned bone media. Image of a representative Western blot, and the graph shows the mean quantifications 6 SEM of 4 different experiments.
Quantification was done on the 50 kDa bands. *: p,0.05.
doi:10.1371/journal.pone.0033543.g004
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resorption.
– Osteoclast number (N. Oc/BV, /mm
2)
Human explant cultures
Human cartilage samples were harvested from patients who
were undergoing total knee replacement surgery for medial OA, in
accordance with the French National Authority Legislation for the
collection of human tissues. This study was specifically approved
by the Institutional Review Board: IRB Nu 0000383). As required
by the French bioethics law and the local IRB, the need for
informed consent was waived since these tissues were surgical
waste of routine joint replacement surgery, and since there was no
patient private information being collected. All participants
received an information note explaining the purpose of the study
and were asked for their non opposition to participate.
Samples were collected from the posterior surface of the
unaffected femoral condyle, using a bone-marrow trephine that
ensured that the explants removed were equal in size (3.5-mm
diameter). Bone and cartilage explants were separated mechan-
ically, and cultured separately. All cultures were conducted in a
humidified atmosphere of 95% air-5% CO2. After culturing for
72 h in BGJb medium (US Biological, MA, USA), bone explants
were serum starved for 24 h hours, and the pre-stimulated with
IL-1b at 10 ng/ml for 24 hours (R&D systems, France). They
were then cultured for 48 h with 0.01 or 1 mM( E
28 or E
26)1 7 b-
estradiol (Sigma-Aldrich, MO, USA), or 1 mM pamidronate
(PAM). The explants were then washed and cultured in fresh
medium for 24 hours. Cartilage explants were cultured in phenol-
red free DMEM with 10% FCS and a cocktail of antibiotics until
being subjected to stimulation with IL-1b at 10 ng/ml for
24 hours. Bone culture supernatants were then transferred onto
cartilage explants for 72 h.
The proteoglycan content in the media was measured as
sulfated glycosaminoglycan by a colorimetric assay using di-
methylmethylene blue [37]. Aggrecan neoepitopes were analyzed
by Western blotting using a monoclonal antibody that recognizes
the human aggrecan neoepitopes ARGS
374 sequences (ab3773,
Abcam). The culture media (15 ml) used for each condition were
deglycosylated with hyaluronidase at 0.3 mg/ml for 30 min, and
then with chondroitinase ABC (Sigma-Aldrich) at 0.1 U/ml in a
buffer containing 50 nM sodium acetate, 0.1 M Tris-HCl,
pH 6.5, at 37uC for 90 min [38]. Samples were then analyzed
by SDS-PAGE on 8% polyacrylamide gels following standard
procedures.
Finally, to investigate the role of OPG released from bone in
cartilage breakdown, OPG neutralizing antibody, OPG-ab
(MAB805, R&D systems, France) or isotype control was added
to the supernatant of bone cultures, and then transferred to
cartilage explants for 72 hours. Supernatants were then tested for
aggrecan neoepitopes by Western blotting.
Bone mRNA extraction and gene expression
Human bone explants were then collected and processed for
RNA extraction. Bone samples were ground in liquid nitrogen,
and placed in 1 ml Trizol (Invitrogen, UK) for RNA extraction by
centrifuging in chloroform and isopropanol, according to the
manufacturing protocol. Total RNA were transcripted into cDNA
by the cDNA verso Kit (Thermo Fisher Scientific, UK). Relative
mRNA levels were evaluated by quantitative PCR analysis using
LightCycler (Roche Applied Science, France) in Absolute Blue
qPCR SYBR Green (Thermo Fisher Scientific), at a fusion
temperature of 60uC, with 40 cycles and normalized to GAPDH








All statistical analyzes were performed using STATVIEWH
software (SAS Institute, NC, USA). Results are expressed as the
mean 6 SEM of at least 3 different experiments. The effects of
meniscectomy and bone resorption inhibitors were analyzed using
the Wilcoxon rank and Mann-Whitney tests. The latter test was
also used to analyze the different conditions of culture of the
human explants.
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